Sharemaestro Newsreel

Balyasny Asset Management (NERV) discloses 9.99% Minerva Neurosciences ownership via shares and warrants

Balyasny Asset Management L.P. and its affiliates have reported a beneficial ownership of 9.99% in Minerva Neurosciences, Inc. (NERV). This stake comprises 4,654,212 shares, including 4,257,000 shares held directly by Atlas Private Holdings (Cayman) Ltd. and 397,212 shares exercisable from 13,500 warrants. The warrants …

Bernstein Adjusts PT on Regeneron Pharmaceuticals to $756 From $753, Maintains Market Perform Rating

Bernstein has increased its price target for Regeneron Pharmaceuticals (REGN) to $756 from $753, while maintaining a "Market Perform" rating on the stock. This adjustment reflects a modest change in the analyst's valuation, indicating a continued neutral stance on the company's stock performance. The …

Renaissance Technologies LLC Acquires 107,315 Shares of Q32 Bio Inc. $QTTB

Renaissance Technologies LLC significantly increased its stake in Q32 Bio Inc. by acquiring an additional 107,315 shares in the first quarter, bringing its total to 206,915 shares valued at $1.33 million. This comes as Q32 Bio reported better-than-expected quarterly earnings and several other institutional …

How Investors May Respond To Immunocore (IMCR) Turning First-Half Profit Amid Recent Share Price Pullback

Immunocore Holdings plc reported a significant improvement in its financial performance, achieving profitability in the first half of 2026 with net income of US$12.16 million, up from a loss the previous year. This positive shift is driven by increased revenue, though the company's investment …

Balyasny Asset Management (CLRB) discloses 9.99% Cellectar stake via stock and warrants

Balyasny Asset Management and affiliated entities have disclosed a 9.99% beneficial ownership stake in Cellectar Biosciences (CLRB) through a Schedule 13G SEC filing. This stake comprises 220,000 common shares and 578,382 shares issuable upon the exercise of warrants, all held under a 9.99% Beneficial …

Contineum Therapeutics (CTNM): Balyasny group reports 7.14% stake in 13G/A filing

Balyasny Asset Management and its affiliated entities have reported a 7.14% beneficial ownership stake in Contineum Therapeutics (CTNM) Class A common stock through a Schedule 13G/A filing. This equates to 2,335,550 shares, with sole voting and dispositive power, based on 32,723,877 shares outstanding as …

Valneva SE earnings missed by $0.18, revenue fell short of estimates

Valneva SE reported second-quarter earnings per share of $-0.39, missing analyst estimates by $0.18. The company's revenue for the quarter was $40.29 million, falling short of the consensus estimate of $44.17 million. Valneva SE's stock price has declined by -0.53% in the last 3 …

Handelsbanken Fonder AB Has $10.38 Million Stock Position in Axsome Therapeutics, Inc. $AXSM

Handelsbanken Fonder AB significantly increased its stake in Axsome Therapeutics, Inc. by 216.4% in the second quarter, now holding 42,400 shares valued at $10.38 million. This comes despite Axsome Therapeutics missing analyst expectations for both earnings and revenue in its latest quarterly report. The …

GH Research PLC (NASDAQ:GHRS) Receives Average Rating of "Moderate Buy" from Analysts

GH Research PLC (NASDAQ:GHRS) has received an average rating of "Moderate Buy" from analysts, with ten out of twelve recommending a buy and an average 12-month price target of $45.00 against a current price of $28.19. Despite beating quarterly earnings estimates, analysts foresee continued …

Balyasny reports 4.84% Rezolute (RZLT) stake in Schedule 13G/A

Balyasny Asset Management and its affiliated entities have reported a 4.84% beneficial ownership stake in Rezolute, Inc. (RZLT) common stock through a Schedule 13G/A filing. This ownership amounts to 4,662,039 shares held via Atlas Diversified Master Fund, Ltd., representing 4.84% of Rezolute's outstanding shares …

Bronstein, Gewirtz & Grossman, LLC Is Investigating Replimune Group Inc. (REPL) And Encourages Shareholders to Connect

Bronstein, Gewirtz & Grossman, LLC is investigating Replimune Group Inc. (REPL) after the FDA deemed the company's lead trial for its skin cancer drug RP1 "not interpretable," causing a significant drop in stock price. The firm is encouraging shareholders who purchased Replimune securities to …

Arcutis Biotherapeutics (NASDAQ:ARQT) Matches Navellier's Growth Playbook With Accelerating Fundamentals

Sirenia Capital discloses 4.3% Immunome (IMNM) stake in Schedule 13G/A

Sirenia Capital Management LP and Alex Silverstein have reported a 4.3% beneficial ownership stake in Immunome Inc. (IMNM) through an amended Schedule 13G filing. They collectively hold 4,832,279 shares of common stock, representing 4.3% of the 113,250,394 shares outstanding as of May 7, 2026. …

Cyclerion Therapeutics (CYCN): Balyasny group discloses 7.33% equity position

Balyasny Asset Management L.P. and its affiliated entities have disclosed a 7.33% beneficial ownership stake in Cyclerion Therapeutics, Inc. (CYCN). The group holds 317,511 shares of common stock through Atlas Diversified Master Fund, Ltd., exercising sole voting and dispositive power over these shares. This …

Rallybio Corp (RLYB) sees Balyasny group report 0% ownership in 13G/A

Innate Pharma (IPHA) plans August 14, 2026 conference call and webcast

Nektar Therapeutics (NKTR) adds $1.02B cash while posting $85.5M loss

MiNK Therapeutics (NASDAQ:INKT) Stock Rating Lowered by Zacks Research

Balyasny Asset Management (LXEO) discloses 7.84M-share Lexeo Therapeutics stake capped at 9.99%

Balyasny Asset Management and its affiliated entities have disclosed a beneficial ownership of 7,844,311 shares of Lexeo Therapeutics, Inc. (LXEO) common stock, representing 9.99% of the outstanding shares. This stake includes shares directly held by Atlas Diversified Master Fund and Atlas Private Holdings, with …

Inovio Pharmaceuticals (NASDAQ:INO) Upgraded to Strong-Buy at Zacks Research

Zacks Research has upgraded Inovio Pharmaceuticals (NASDAQ:INO) to a "strong-buy" rating. This upgrade comes as the company reported a quarterly loss of $0.07 per share, beating analyst expectations, and anticipates an FDA decision for its key product INO-3107 by October 30, 2026. The company …

Should I Buy GUTS (Fractyl Health, Inc. Common Stock) | AI Analysis, Technical & News Insights

Balyasny group discloses 4.99% Camp4 Therapeutics (CAMP) position with warrant blocker

Balyasny Asset Management and its related entities have disclosed a beneficial ownership of approximately 4.99% in Camp4 Therapeutics Corp. (CAMP). This stake, totaling 2,591,097 shares, includes common stock and shares issuable upon warrant exercise, which are subject to a 4.99% Beneficial Ownership Limitation to …

Aura Biosciences (AURA): Long Focus Capital reports 4.9% ownership

Long Focus Capital Management, LLC and John Helmers have reported a 4.9% beneficial ownership stake in Aura Biosciences, Inc. (AURA) through a Schedule 13G filing. As of June 30, 2026, they beneficially owned 5,119,582 shares of common stock, with shared voting and dispositive power. …

Fennec Pharmaceuticals (FENC) Stock Sees Fair Value Lift As Analysts Raise PEDMARK Views

Analysts have raised their fair value estimate for Fennec Pharmaceuticals (FENC) from US$15.33 to US$17.67 per share, attributing this increase to stronger-than-expected PEDMARK revenue, its expanded use across various tumor types, and improved operating leverage. Several firms, including B. Riley, Wedbush, and H.C. Wainwright, …

Sarepta Therapeutics (SRPT) submits Form 13F showing one entry and $0 value

Sarepta Therapeutics, Inc. has filed a Form 13F as an institutional investment manager, detailing one information table entry with an aggregate reported value of $0. The filing, signed by Executive Vice President and CFO Ryan Wong, indicates no other included managers. This quarterly report …

Balyasny Asset Management (CBIO) discloses 6.03% Crescent Biopharma ownership

Balyasny Asset Management L.P. and its affiliated entities have reported a 6.03% beneficial ownership stake in Crescent Biopharma, Inc., totaling 1,662,917 shares of Class A common stock. This ownership is primarily held through Atlas Private Holdings (Cayman) Ltd. and Atlas Diversified Master Fund, Ltd. …

Zacks.com featured highlights include BioMarin Pharmaceutical, Invesco, Centene Corporation, Hewlett Packard Enterprise and Gibraltar Industries

For Immediate Release Chicago, IL – August 14, 2026 – Stocks in this week's article are BioMarin Pharmaceutical BMRN, Invesco IVZ, Centene Corporation CNC, Hewlett Packard Enterprise HPE and Gibraltar Industries ROCK. 5 Undervalued Price-to-Book Stocks Worth Buying in August There are several different …

Four Innate Pharma executives set to appear in Aug. 14 webcast

Capricor shares spike on CEO comments; Cytokinetics sues Bristol Myers

Capricor Therapeutics shares jumped over 60% after its CEO indicated the FDA is open to reviewing an updated Duchenne muscular dystrophy cell therapy submission. Separately, Cytokinetics is suing Bristol Myers Squibb to protect patents for its heart drug Myqorzo, accusing BMS of attempting to …

Erasca, Inc. (NASDAQ:ERAS) Receives Average Rating of "Moderate Buy" from Brokerages

Erasca, Inc. (NASDAQ:ERAS) has received a "Moderate Buy" consensus rating from eleven brokerages, with an average 12-month price target of $21.91. Despite a recent 3.9% decline in shares and missing analyst expectations for its quarterly loss, institutional investors hold a significant 67.78% of the …

Does Wider Losses And New US$149.2m Shelf Offering Change The Bull Case For Trevi (TRVI)?

Trevi Therapeutics, Inc. reported wider net losses and basic loss per share in Q2 2026, alongside filing a US$149.2 million shelf registration for 8,000,000 common shares. This new financing overhang adds to existing concerns about potential dilution and weighs against the company's investment narrative, …

Handelsbanken Fonder AB Acquires Shares of 287,900 Tango Therapeutics, Inc. $TNGX

Handelsbanken Fonder AB has acquired 287,900 shares of Tango Therapeutics, Inc. (NASDAQ:TNGX) for approximately $9 million, establishing a 0.20% stake in the company. Institutional investors now collectively own nearly 79% of Tango Therapeutics, a clinical-stage biotechnology company focused on precision cancer medicines. The company …

Ginkgo Bioworks Holdings, Inc. (DNA) Q2 2026 Earnings Report - Results, Call & Slides

Sei Investments Co. Buys Shares of 99,627 MeiraGTx Holdings PLC $MGTX

Sei Investments Co. has acquired 99,627 shares of MeiraGTx Holdings PLC (MGTX) worth approximately $863,000, as part of broader institutional investor interest in the company. Despite significant insider selling totaling $1.68 million over the last three months, MeiraGTx reported strong quarterly EPS of $1.71, …

Inhibrx Biosciences, Inc. (NASDAQ:INBX) Given Consensus Recommendation of "Hold" by Brokerages

Inhibrx Biosciences (NASDAQ:INBX) has received a consensus "Hold" recommendation from brokerages, with an average 12-month price target of $150.00. The company recently reported a quarterly EPS of -$2.34, missing analyst estimates, and institutional investors now own 82.46% of the stock. BlackRock Inc. notably acquired …

Arcutis Biotherapeutics, Inc. (NASDAQ:ARQT) Receives Average Recommendation of "Moderate Buy" from Brokerages

Arcutis Biotherapeutics, Inc. (NASDAQ:ARQT) has received an average "Moderate Buy" recommendation from analysts, with an average 12-month price target of $35.57. The company recently exceeded quarterly earnings and revenue expectations, reporting $0.11 EPS against an anticipated $0.06 and $129.86 million in revenue versus $118.85 …